Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Hospital Universitario Dr. Jose E. Gonzalez
10 participants
Feb 1, 2026
INTERVENTIONAL
Conditions
Summary
In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
Eligibility
Inclusion Criteria5
- Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant
- ECOG 0-2
- Women of reproductive age who agree on getting a contraceptive method
- Subjects who fulfill Lugano´s criteria for disease activity
- Subjects who voluntarily accept to participate in this study
Exclusion Criteria4
- Active bacterial, viral or fungal infection
- Subjects who have already received an autologous o allogeneic stem cell transplantation
- Subjects with other active neoplasias
- Subjects with end-stage failure
Interventions
Subjects will receive 2 step up doses of Epcoritamab (0.16 mg and 0.8 mg) followed by 12 mg weekly, for a total of three 21-day cycles (8 applications)
Subjects will receive gemcitabine 1000 mg/m2 on days 1 and 15 of the three 21-day cycles.
Subjects will receive oxaliplatin 100 mg/m2 on day 1 of three 21-day cycles.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07451652